EP1137800A1 - Method for purifying or isolating viral nucleic acids - Google Patents
Method for purifying or isolating viral nucleic acidsInfo
- Publication number
- EP1137800A1 EP1137800A1 EP99950544A EP99950544A EP1137800A1 EP 1137800 A1 EP1137800 A1 EP 1137800A1 EP 99950544 A EP99950544 A EP 99950544A EP 99950544 A EP99950544 A EP 99950544A EP 1137800 A1 EP1137800 A1 EP 1137800A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- buffer
- nucleic acid
- nucleic acids
- plasma
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Definitions
- the present invention relates to a method for isolating viral nucleic acids from liquids containing virus particles, such as e.g. Plasma or other liquids, the nucleic acids being obtained in pure form.
- the invention relates to the detection of viruses present in liquids, especially in plasma pools.
- the present invention relates in particular to a method for preparing samples for nucleic acid amplification techniques and a kit for carrying out the method.
- RNA amplification techniques are now often used assays such as assays based on polymerase chain reaction (PCR), branched DNA detection (bDNA) or nucleic acid sequence based amplification (NASBA) are used.
- PCR polymerase chain reaction
- bDNA branched DNA detection
- NASBA nucleic acid sequence based amplification
- the detection limit of the commercially available assays is around 100 to 400 DNA / RNA copies / ml plasma .
- Amplicor HCV Amplicor HBV monitor
- Amplicor HIV-1 monitor Amplicor HIV-1 monitor
- the detection limit of the commercially available assays for the detection of viruses is a problem. If, for example, only one out of 96 samples were virus-positive, the total virus concentration would drop to about 1/100 due to the dilution factor in the plasma pool , ie a value that is usually below the detection limit of the particular assay used. For example, if 1000-4000 RNA copies / ml HCV are measured in a single sample, there would only be about 10-40 copies / ml HCV in a 96-fold plasma pool (using this one contaminated and 95 virus-free individual samples with the same volume). which have so far not been detected by the commercially available assays. This would result in the contamination of the entire plasma pool and the transmission of the viruses to a large number of plasma receivers.
- the precipitation of virus particles from liquids using polyethylene glycol (PEG) has been a standard technique for concentrating viruses with low centrifugal force since the early 1970s (Yamamoto et al., Virology 40 (1970) 734; Morandi et al., J. Clin. Microbiol. 36 (1998) 1534-38).
- PEG polyethylene glycol
- the liquid is mixed with PEG and NaCl. Precipitation takes place in the cold, and the virus (protein) / PEG precipitates are then obtained by centrifugation.
- the further processing steps preservation of the vital virus particles, disruption of the virus particles etc. ultimately depend on the scientific question.
- An alternative method is the ultracentrifugation of viruses in liquids.
- the concentration of the virus particles on the bottom of the centrifugation vessel is achieved solely by the centrifugal force acting over a long period of time.
- this method can only be used to a limited extent for HCV, since the HCV particles are often in the lipid layer and therefore cannot be prepared quantitatively.
- RNA viruses e.g. HCV or HIV-1
- chaotropic denaturans guanidine isothiocyanate GIT denatures all proteins (including RNA-degrading RNases) so that the nucleic acids are freely available in solution and are protected against degradation.
- phenol / chloroform can be used as the denaturing agent (Cox, Methods Enzymol. 12B (1968) 120; Glisen et al., Biochemistry 13 (1974) 2633; Ullrich et al., Science 196 (1977) 1313).
- this is disadvantageous because of the toxicity, disposal, etc. of the agents used.
- the extracted nucleic acids can finally be purified by various methods.
- the binding of the nucleic acids to silicon matrices is a widely used method.
- Kits for carrying out the silicon method are commercially available from the companies QIAGEN (Hilden, DE), Macherey-Nagel (Düren, DE), Boehringer-Mannheim (Mannheim, DE), Organon Teknika (Turnhout, BE) and various other providers.
- the end product obtained is a mostly highly purified nucleic acid present in neutral solution (H 2 O or Tris buffer) (Vogelstein and Gillespie, Proc. Natl. Acad. Sci. USA 76 (1979) pages 615-619; Boom et al., J Clin Microbiol. 28 (1990) 495).
- the object of the present invention is therefore to provide a method with which viruses, in particular HBV, HCV and HIV, can be detected and / or quantified in blood plasma pools. It is also an object of the present invention to provide a virus detection method that enables highly sensitive and rapid testing of blood products (such as required for platelets) that can only be kept for a relatively short time.
- the present invention thus relates to a method for the purification or isolation of nucleic acids from virus particles which may be present in liquid biological sample material, which is characterized in that
- GIT buffer 6 M guanidine isothiocyanate (GIT), 200 mM dithiothreitol (DTT), 100 mM Tris, pH 6.5).
- the biological sample material can be e.g. Plasma samples (preferably from plasma pools), other blood products or other liquids that can be contaminated with viruses.
- RNA or DNA samples obtained in step c) can then, after purification, be examined by NAT for possible contamination with viruses.
- the virus-enriched mixture from stage c) can preferably be transferred directly to a commercially available kit for isolating viral DNA / RNA.
- the invention relates to a method for purifying viral nucleic acids, which the above.
- Steps a) to c) and the additional stages d) and e) comprises, wherein one
- stage d) the mixture obtained in stage c) optionally with the same volume of lysis buffer from a commercially available virus RNA / DNA isolation kit (for example "Buffer AVL” from the “QIAmp Viral RNA Kit", QIAGEN or “binding") Buffer "of the” High Pure Viral RNA Kit “Boehringer Mannheim or other manufacturers) mixes, then the double volume of 96-99% ethanol is added, and one
- step e) cleaning is carried out on a silicon matrix.
- the addition of the lysis buffer can be dispensed with in stage d) and ethanol can be added immediately.
- the same volume of GIT buffer can be added instead of the lysis buffer.
- the purified nucleic acids are then present in the eluate.
- lysis buffers All buffers that are supplied by the manufacturer of the virus DNA / RNA isolation kits are preferred as lysis buffers, but other lysis buffers that preferably contain GIT are also suitable.
- the silicon matrices usually supplied with the kits (.B. As a filter, in the form of beads, etc.) are preferred in the context of the present invention. However, other materials can also be used which bind RNA or DNA and thereby enable their purification.
- the method is preferably used to prepare biological samples, in particular samples from plasma pools, for subsequent use in NAT, the purified nucleic acids obtained being able to be used directly in the amplification process without further pretreatment.
- NAT PCR, bDNA, NASBA etc.
- the nucleic acids are in particular DNA or RNA from HCV, HBV and HIV (in particular HIV-1). According to a particular embodiment of the invention, the method is carried out by
- a plasma sample is used and the sample volume is max.
- step b) centrifuged for 15-20 minutes at 4 ° C and approx. 3000 g,
- step c) add 300 to 400 ⁇ l GIT buffer (see above) to dissolve the pellet and dissolve for approx. 10 min at 56 ° C and
- step d) the solution is mixed with the lysis buffer of a commercial virus RNA kit (see above) in a ratio of 1: 1.
- the lysate is mixed with 300 to 400 ⁇ l GIT-containing AVL buffer (see above) in a ratio of 1: 1 and then mixed with 600 to 800 ⁇ l 96-99% ethanol, e) cleaning is carried out on silicon matrix,
- the purified nucleic acids being present in the eluate.
- the nucleic acids initially bound are washed and then eluted from the column.
- This method is preferably used for sample preparation for the detection of HCV, HBV or HIV (in particular HIV-1) from pooled plasmas from blood donors.
- the virus RNA is then used using known nucleic acid amplification techniques (e.g. PCR, bDNA or NASBA) amplified and detected according to generally known methods (such as by hybridization with the help of labeled probes etc.).
- the invention further relates to a kit for carrying out the cleaning or isolation method according to the invention or for carrying out the method for preparing biological samples for NATs, which contains defined amounts of PEG, sodium chloride, GIT buffer and ethanol in suitable storage containers, which make it possible to e.g. to subject a predetermined plasma sample volume to the method.
- the kit preferably contains polyethylene glycol PEG 6000 and sodium chloride in the form of an aqueous solution, according to a particular embodiment 50% PEG 6000 and 5 M aqueous NaCl solution.
- the kit contains for preparing a plasma sample of 4.8 ml volume each a) 300 ⁇ l of 50% PEG 6000,
- kits for the detection of HCV, HBV or HIV from pooled plasmas from blood donors is made available for the first time. or isolation method or sample preparation method.
- the present invention has the advantage that the (highly) purified nucleic acids obtained in stage e) of the method are not contaminated with PEG, since this is completely removed by washing the nucleic acids bound to the matrix. They are also enriched in such a way that about 6 IU / ml HCV-RNA (corresponding to approx. 20 RNA copies per ml) can still be detected with the help of commercially available NAT assays. A corresponding detection limit is reached for HBV and HIV-1.
- This detection limit enables in particular testing of samples from plasma pools, whereby the requirements set by the Paul Ehrlich Institute with regard to a minimum sensitivity of 5000 IU HCV / ml per individual sample not only meet but also by a lot (by a factor of at least about 8 in pools of 96).
- the present invention makes it possible for the first time to test plasma pools in which only one of 96 individual samples is contaminated with 1000 IU / ml HCV, which corresponds to a concentration of approximately 10 IU / ml in the pool.
- Plasma pools can thus be tested for the first time with commercial NAT tests with high sensitivity for the presence of virus particles, whereby the need for single-sample analysis is eliminated due to the greatly improved sensitivity and significantly reduced detection limit due to the sample preparation.
- the invention is preferably used for the detection of HCV, HBV and HIV-1 from pooled plasmas from blood donation services, which currently comprise 96 individual samples as standard.
- the cleaning or isolation method according to the invention is distinguished from an ultracentrifugation protocol for the enrichment of virus particles from liquids in that expensive ultracentrifuge equipment can be dispensed with, since each standard cooling centrifuge which can hold 5-15 ml tubes, is suitable for performing the method.
- a parallel processing of a large number of samples is also possible in the context of the present invention, i.e. usually more than 60 samples, while when using ultracentrifuges, due to the usually very small number of available spaces for tubes in the centrifuge (often fewer than 12), only a few samples can be processed at the same time.
- the method of the present invention Compared to ultracentrifugation, the method of the present invention also achieves faster sedimentation of the virus particles (approx. 40 min over several hours).
- the entire method for the detection of viruses in liquid samples using commercially available NAT assays thus requires no more than about 7 hours.
- it can also be used successfully if the test only releases blood products that are stable for a short time (3-4 days), such as thrombo- bozyten, depends.
- the enrichment of the virus particles is achieved exclusively by ultracentrifugation, it takes about 2 days, which cannot be used for the release of platelets.
- the present invention thus allows for the first time the highly sensitive testing of blood products (such as platelets) that can only be kept for a relatively short time.
- the method according to the invention is further characterized in that less sample material has to be used to carry out the NAT assays, since the entire plasma pool can be tested instead of the individual samples. Furthermore, the method is particularly suitable because of the lower cost and the enormous time saving for blood donation services and blood banks, where several 1000 samples have to be tested per day.
- the invention also has the particular advantage that lipid-associated virus particles (e.g. HCV) can also be prepared quantitatively and detected with high sensitivity, while they can remain in the fat phase floating above when enriched by ultracentrifugation.
- lipid-associated virus particles e.g. HCV
- the method according to the invention Compared to standard protocols for isolating virus nucleic acids from liquids, the method according to the invention has the advantage that it is not limited to very small test volumes (100-200 ⁇ l), since samples of up to 10 ml volume can be used.
- the sample preparation according to the invention compared to the prior art, the sensitivity of virus copies / ml detectable by 20 or less, compared to the prior art, makes it possible to detect or quantify viruses even in samples with a very low virus titer. In this way, increased safety is achieved when using blood (plasma) products.
- Virus particles are concentrated from a large (plasma) sample volume (max. 10 ml). This is done by precipitation with PEG 6000 (approx. 3% by weight, ie 50 g PEG ad 100 ml H 2 0 (w / v)) and NaCl (approx. 150 mM of an aqueous solution) for approx. 15-20 min in the cold (4 ° C) with subsequent centrifugation (15-20 min, 4 ° C, 3000 g).
- PEG 6000 approximately 3% by weight, ie 50 g PEG ad 100 ml H 2 0 (w / v)
- NaCl approx. 150 mM of an aqueous solution
- the pellet After decanting the supernatant, the pellet is dissolved in 300-400 ⁇ l GIT buffer (6 M GIT, 200 mM DTT, 100 mM Tris, pH 6.5) by incubation at approx. 56 ° C for approx. 10 min.
- GIT buffer 6 M GIT, 200 mM DTT, 100 mM Tris, pH 6.5
- the lysate is mixed with the lysis buffer (see above) of a commercial virus RNA isolation kit (eg QIAamp Viral RNA Kit, QIAGEN, or High Pure Viral RNA Kit, Boehringer) in a ratio of 1 : 1 mixed and then mixed with twice the volume of EtOH (96-99%).
- a commercial virus RNA isolation kit eg QIAamp Viral RNA Kit, QIAGEN, or High Pure Viral RNA Kit, Boehringer
- the nucleic acid-GIT-EtOH mixture is placed on a nucleic acid-binding silicon membrane (as a centrifugation column in the manual or as a Multiwell 96 system in the machine variant of various commercial suppliers, see above) and according to the test instructions of the Manufacturer processed until the elution of the purified RNA / DNA.
- a nucleic acid-binding silicon membrane as a centrifugation column in the manual or as a Multiwell 96 system in the machine variant of various commercial suppliers, see above
- the tubes are then centrifuged at 3000 g for 15-20 min at 4 ° C. in order to sediment the precipitated PEG / virus complexes.
- the lysate is mixed with 300-400 ⁇ l lysis buffer of a commercial virus RNA isolation kit (eg QIAamp Viral RNA Kit (see below), QIAGEN, or High Pure Viral RNA Kit, Boehringer) in a ratio of 1: 1 and then with 600-800 ⁇ l 96-99% EtOH added.
- a commercial virus RNA isolation kit eg QIAamp Viral RNA Kit (see below), QIAGEN, or High Pure Viral RNA Kit, Boehringer
- the mixture is e.g. In the manual variant using the QIAamp Viral RNA Kit, put it in two 630 ⁇ l portions on the centrifugation columns (part of the "Viral RNA Kit", see above) and proceed according to the manufacturer's instructions. In the machine version (QIAamp 96 Viral RNA Test Kit), the 7 ml tubes with the lysis mixture are placed in the primary tube adapter of the BioRobot 9604 (QIAGEN) and processed automatically until the nucleic acids are eluted.
- any established NAT method for example PCR
- 10-50 ⁇ l of H 2 0 or in an elution buffer supplied by the kit manufacturer
- Example 2 The method shown in Example 2 was tested on the basis of several hundred samples defined in terms of their virus quantity and a detection limit of approximately 20 virus copies / ml by using the nucleic acid eluates in the Amplicor test systems HBV Monitor, HCV Test and HIV-1 Monitor (Hoffmann -La Röche) determined. The results are shown in Tab. 1.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19856415A DE19856415C2 (en) | 1998-12-08 | 1998-12-08 | Process for the purification or isolation of viral nucleic acids |
DE19856415 | 1998-12-08 | ||
PCT/EP1999/007093 WO2000034510A1 (en) | 1998-12-08 | 1999-09-23 | Method for purifying or isolating viral nucleic acids |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1137800A1 true EP1137800A1 (en) | 2001-10-04 |
EP1137800B1 EP1137800B1 (en) | 2003-04-09 |
Family
ID=7890263
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99950544A Expired - Lifetime EP1137800B1 (en) | 1998-12-08 | 1999-09-23 | Method for purifying or isolating viral nucleic acids |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1137800B1 (en) |
AT (1) | ATE236999T1 (en) |
AU (1) | AU6329099A (en) |
DE (2) | DE19856415C2 (en) |
ES (1) | ES2196870T3 (en) |
HK (1) | HK1042116A1 (en) |
WO (1) | WO2000034510A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10006662A1 (en) | 2000-02-15 | 2001-08-23 | Antigen Produktions Gmbh | Sample vessel for stabilizing and isolating nucleic acid, contains a lytic solution that stabilizes nucleic acid and a solid phase that binds it, especially for sampling whole blood |
BRPI0509148B8 (en) | 2004-03-22 | 2021-05-25 | Abbott Products Gmbh | oral pharmaceutical compositions of products containing lipase, in particular pancreatin containing surfactants, their uses and respective manufacturing processes |
JP5140586B2 (en) | 2005-07-29 | 2013-02-06 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Production of sterile pancreatin powder |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
US9198871B2 (en) | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
EP2027263B1 (en) * | 2006-05-22 | 2012-07-11 | Abbott Products GmbH | Process for separating and determining the viral load in a pancreatin sample |
US10072256B2 (en) | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
DE102008023297B4 (en) | 2008-05-08 | 2014-06-26 | Aj Innuscreen Gmbh | Method for enrichment and isolation of nucleic acids or viruses |
DE102015215894B4 (en) | 2015-03-26 | 2017-11-30 | Aj Innuscreen Gmbh | Method of enriching biomolecules and removing biomolecules from a biological sample |
PL3487869T3 (en) | 2016-07-25 | 2024-03-18 | Ist Innuscreen Gmbh | Method for enriching biomolecules and for removing the biomolecules from a biological sample |
CN111850171A (en) * | 2020-08-03 | 2020-10-30 | 浙江大学 | Method for detecting lentivirus in deep sea sediment sample |
DE102021104319A1 (en) | 2021-02-23 | 2022-08-25 | Aj Innuscreen Gmbh | Process for the simultaneous isolation of nucleic acids from sedimentable and non-sedimentable biomolecules in water samples |
-
1998
- 1998-12-08 DE DE19856415A patent/DE19856415C2/en not_active Expired - Fee Related
-
1999
- 1999-09-23 AT AT99950544T patent/ATE236999T1/en not_active IP Right Cessation
- 1999-09-23 AU AU63290/99A patent/AU6329099A/en not_active Abandoned
- 1999-09-23 EP EP99950544A patent/EP1137800B1/en not_active Expired - Lifetime
- 1999-09-23 DE DE59905002T patent/DE59905002D1/en not_active Expired - Fee Related
- 1999-09-23 WO PCT/EP1999/007093 patent/WO2000034510A1/en active IP Right Grant
- 1999-09-23 ES ES99950544T patent/ES2196870T3/en not_active Expired - Lifetime
-
2002
- 2002-04-02 HK HK02102445.5A patent/HK1042116A1/en unknown
Non-Patent Citations (1)
Title |
---|
See references of WO0034510A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1137800B1 (en) | 2003-04-09 |
HK1042116A1 (en) | 2002-08-02 |
DE19856415C2 (en) | 2001-06-07 |
DE59905002D1 (en) | 2003-05-15 |
ES2196870T3 (en) | 2003-12-16 |
WO2000034510A1 (en) | 2000-06-15 |
DE19856415A1 (en) | 2000-06-15 |
ATE236999T1 (en) | 2003-04-15 |
AU6329099A (en) | 2000-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2501811B1 (en) | Method for selective enrichment and isolation of microbial and optional additionally of viral nucleic acids | |
DE69734263T2 (en) | Process for isolating ribonucleic acids. | |
DE69031237T3 (en) | Process for the purification of nucleic acids | |
DE69029563T2 (en) | Process for nucleic acid extraction and PCR amplification without the use of proteolytic enzyme | |
EP2071037B1 (en) | Vessel for blood sampling | |
EP1851313B1 (en) | Method for isolating nucleic acids, wherein the nucleic acids are immobilised on a matrix at elevated temperatures | |
DE69031957T2 (en) | Process for the extraction, amplification and detection of nucleic acids from whole blood | |
DE69109275T2 (en) | METHOD FOR INSULATING MACROMOLECULES BY MEANS OF MAGNETICALLY EXTRACTABLE BALLS THAT BIND THE MACROMOLECULES UNSPECIFICALLY. | |
WO2000024927A1 (en) | Methods and means for isolating and purifying nucleic acids on surfaces | |
DE3639949A1 (en) | METHOD FOR SEPARATING LONG CHAIN NUCLEIC ACIDS | |
EP2382323B1 (en) | Preparation and amplification of nucleic acids by means of magnetic particles | |
EP1137800B1 (en) | Method for purifying or isolating viral nucleic acids | |
DE102006020872A1 (en) | Method for nucleic acid isolation and device for nucleic acid isolation | |
EP2264184A1 (en) | Method for amplifying DNA using tetraethylenglycol, kit of parts for same and use of same | |
EP2297361A1 (en) | Rapid analytical method for mixed biological samples | |
DE102014118532A1 (en) | Device having a filter layer and method for recovering nucleic acids from formalin-fixed and paraffin-embedded samples | |
EP2041281B2 (en) | Method for insulating in parallel double and single-stranded nucleic acids and for selectively removing double-stranded nucleic acids from a mixture of double and single-stranded nucleic acids | |
DE69722159T2 (en) | Method for reducing inhibitors of nucleic acid hybridization | |
DE102005054206A1 (en) | Method for automatic processing of pooled sample for testing donated blood and blood products, by combining the samples to sample pool, addition of solution to the enriched sample pool and resuspension of the sample pool in the solution | |
EP0818542A1 (en) | Method for the stabilisation of nucleic acids prior to their isolation from blood samples | |
DE20117746U1 (en) | Reaction rooms containing complex storage-stable reagent formulations and test kit for the detection and isolation of pathogenic microbial nucleic acids | |
DE60215226T2 (en) | METHOD FOR THE ISOLATION OF DNA | |
DE102006032610C5 (en) | Method for the parallel isolation of viral nucleic acids | |
WO2022242931A1 (en) | Process for purifying nucleic acids, in particular in a microfluidic apparatus | |
EP1697540A1 (en) | Method for enriching and stabilising components which contain dna and which are made of biological materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010423 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
17Q | First examination report despatched |
Effective date: 20011009 |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030409 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT Effective date: 20030409 Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030409 Ref country code: FR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030409 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030409 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D Free format text: NOT ENGLISH |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D Free format text: GERMAN |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030709 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030709 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030709 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030709 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
GBT | Gb: translation of ep patent filed (gb section 77(6)(a)/1977) | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030923 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20030923 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030930 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030930 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030930 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030930 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FD4D Ref document number: 1137800E Country of ref document: IE |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2196870 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
EN | Fr: translation not filed | ||
26N | No opposition filed |
Effective date: 20040112 |
|
BERE | Be: lapsed |
Owner name: *FENNER THOMAS Effective date: 20030930 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20070920 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20070912 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20070919 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20071024 Year of fee payment: 9 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1042116 Country of ref document: HK |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20080923 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090401 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080923 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20080924 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080923 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20080924 |